EV-targeted tumor therapies have been proposed because they can carry several immunosuppressive molecules, such as CTLA-4, PD-L1, TGF-β1, FasL, and TRAIL, which make them possible candidates for developing targeted therapies [64, 65]. This evidence concerns the gene TNFSF10 and neoplasm.